Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash ...

Vaxart (VXRT) Q4 2024 Earnings Call March 20, 2025 04:30 PM ET Company Participants Edward Berg - Senior VP & General CounselSteven Lo - CEO & Member of the Board of DirectorsJames Cummings - Chief Medical OfficerSean Tucker - Senior VP & Chief Scientific OfficerPhillip Lee - Chief Financial OfficerCheng Li - Director - Equity ResearchLiang Cheng - Senior Research AssociateRaymond Stapleton - EVP & Chief Technology Officer Conference Call Participants Madison Elsaadi - Equity Research Analyst - Healthcare O ...